Nutrition and schizophrenia: Beyond omega-3 fatty acids

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 70, Issue 4, 2004, Pages 417-422

  Peet, Malcolm ^a  

^a Swallownest Court Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; SATURATED FATTY ACID;

CLINICAL TRIAL; CONFERENCE PAPER; DIET SUPPLEMENTATION; FAT INTAKE; GLUCOSE INTAKE; HUMAN; INSULIN RESISTANCE; LIPID DIET; METABOLIC SYNDROME X; NERVE FIBER GROWTH; NUTRITION; PRIORITY JOURNAL; PROGNOSIS; SCHIZOPHRENIA; SUGAR INTAKE;

EID: 1842609974     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2003.12.019     Document Type: Conference Paper

References (50)

1. A.F. Jorm, A.E. Korten, B. Rodgers, et al., Helpfulness of interventions for mental disorders: beliefs of health professionals compared with the general public, Br. J. Psychiatry 171 (1997) 233-237.
2. A. Geary, The Food and Mood Handbook, Thorsons Publishers, London, 2001.
3. M. Peet, J. Laugharne, N. Rangarajan, D. Horrobin, G. Reynolds, Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients, J. Psychiatr. Res. 29 (1995) 227-232.
4. A.L. Glen, E.M. Glen, D.F. Horrobin, et al., A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases, Schizophr. Res. 12 (1994) 53-61.
5. M. Arvindakshan, S. Sitasaward, V. Debsikdar, et al., Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients, Biol. Psychiatry 53 (2003) 56-64.
6. M.M. Khan, D.R. Evans, V. Gunna, R.E. Scheffer, V.V. Parikh, S.P. Mahadik, Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first episode of psychosis and after years of treatment with antipsychotics, Schizophr. Res. 58 (2002) 1-10.
7. J.K. Yao, D.P. van Kammen, J.A. Welker, Red blood cell membrane dynamics in schizophrenia. II Fatty acid composition, Schizophr. Res. 13 (1994) 217-226.
8. J. Assies, R. Lieverse, P. Vreken, R.J.A. Wanders, P.M. Dingemans, D.H. Linszen, Significantly reduced docosahexaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group, Biol. Psychiatry 49 (2001) 510-522.
9. J.K. Yao, S. Leonard, R.D. Reddy, Membrane phospholipid abnormalities in post mortem brains from schizophrenic patients, Schizopr. Res. 42 (2000) 7-17.
10. J.R. Hibbeln, K.K. Makino, C.E. Martin, F. Dickenson, J. Boronow, W.S. Fenton, Smoking, gender and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder, Biol. Psychiatry 53 (2003) 431-441.
11. K. Hopper, J. Wanderling, Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from ISOS, the WHO collaborative follow up project, Schizophr. Bull. 26 (2000) 835-846.
12. N. Jablensky, N. Sartorius, G. Ernberg, et al., A. Schizophrenia: manifestations, incidence and course in different cultures: a world health organisation ten-country study. Psychol. Med, Monograph Suppl. 20 (1992) 1-97.
13. World Health Organisation. Schizophrenia: An International Follow-up Study. Wiley, New York, 1979.
14. O. Christensen, E. Christensen, Fat consumption and schizophrenia, Acta Psychiatr. Scand. 78 (1988) 587-591.
15. K.S. Vaddadi, C.J. Gilleard, R.H.S. Mindham, R.A. Butler, A controlled trial of prostaglandin E precursor in chronic neuroleptic-resistant schizophrenic patients, Psychopharmacology 88 (1986) 362-367.
16. K.S. Vaddadi, P. Courtney, C.J. Gilleard, M.S. Manku, D.F. Horrobin, A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia, Psychiatry Res. 27 (1989) 313-323.
17. A. Wolkin, B. Jordan, E. Peselow, M. Rubenstein, J. Petrosen, Essential fatty acid supplementation in tardive dyskinesia, Am. J. Psychiatry 143 (1986) 912-914.
18. D.O. Rudin, The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra, Biol. Psychiatry 16 (1981) 837-850.
19. J.E. Mellor, J.D.E. Laugharne, M. Peet, Omega-3 fatty acid supplementation in schizophrenia patients, Hum. Psychopharmacol. 11 (1996) 39-46.
20. S.R. Kay, A. Fiszbein, L.A. Apler, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr. Bull. 13 (1987) 261-276.
21. W. Guy, ECDEU Assessment Manual for Psychopharmacology. VS Department of Health, Education and Welfare, Washington, DC; US Government Printing Office, 1976, pp. 76-338.
22. W.S. Fenton, Prevalence of spontaneous dyskinesia in schizophrenia, J. Clin. Psychiatry 61 (Suppl. 4) (2000) 10-14.
23. M. Peet, J. Brind, C.N. Ramchand, S. Shah, G.K. Vanka, Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia, Schizophr. Res. 49 (2001) 243-251.
24. M. Peet, D.F. Horrobin, A dose-ranging exploratory study of the effects of ethyl eicosapentaenoate in patients with persistent schizophrenic symptoms, J. Psychiatry Res. 36 (2003) 7-18.
25. W.S. Fenton, F. Dickerson, J. Boronow, J.R. Hibbeln, M.A. Knable, Placebo-controlled trial of omega-3 fatty acid (ethyl eiscosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia, Am. J. Psychiatry 158 (2001) 2017-2074.
26. R.A. Emsley, C.C. Mybury, P.P. Oosthuizen, S.J. Van Rensburgh, Randomised placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia, Am. J. Psychiatry 159 (2002) 1596-1598.
27. M. Peet, Dietary predictors of schizophrenia and depression. Presented at Nineth European Nutritional Conference, Rome, 2003.
28. J.A. Gorski, S.R. Zeiler, S. Tamonski, K.R. Jones, Brain-derived neurotrophic fator is required for the maintenance of cortical dendrites, J. Neurosci. 23 (2003) 6856-6865.
29. R. Molteni, R.J. Barnard, Z. Ying, C.K. Roberts, F.A. Gomez-Pinilla, High-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning, Neuroscience 112 (2002) 803-814.
30. C.S. Weickert, T.M. Hyde, B.K. Lipska, M.M. Herman, D.R. Weinberger, J.E. Kleinman, Reduced brain derived neurotrophic factor in prefrontal cortex of patients with schizophrenia, Mol. Psychiatry 8 (2003) 5610-5920.
31. H.C. Trowell, D.P. Burkitt, Western Diseases: their Emergence and Prevention, Edward Arnold, London, 1983.
32. E.F. Torrey, Schizophrenia and Civilisation, Jason Aronson, New York, 1980.
33. E.M. Goldner, L. Hsu, P. Waraich, J.M. Somers, Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature, Can. J. Psychiatry 47 (2002) 833-843.
34. E.F. Torrey, J. Miller, The Invisible Plague, Rutgers University Press, New Bunswick, 2001.
35. A. Scull, Was insanity increasing. A response to Edward Hare, Br. J. Psychiatry 144 (1984) 432-436.
36. J.E. Cooper, N. Sartorius, Cultural and temporal variations in schizophrenia: a speculation on the importance of industrialisation, Br. J. Psychiatry 130 (1977) 50-55.
37. E. Hare, Schizophrenia as a recent disease, Br. J. Psychiatry 153 (1988) 521-531.
38. V.J. Knapp, Major dietary changes in nineteenth century Europe, Perspect. Biol. Med. 31 (1988) 188-193.
39. T.L. Cleave, The Saccharine Disease, John Wright & Sons, Bristol, 1974.
40. S.B. Eaton, M. Konner, M. Schostak, Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective, Am. J. Med. 84 (1988) 739-749.
41. S.B. Eaton, S.B. Eaton III, M.J. Konner, Paleolithic nutrition revisited: a twelve year retrospective on its nature and implications, Eur. J. Clin. Nutr. 51 (1997) 207-216.
42. A. Leaf, P.C. Weber, A new era for science in nutrition, Am. J. Clin. Nutr. 45 (1987) 1048-1053.
43. L. Henderson, J. Gregory, G. Simon, The National Diet and Nutrition Survey: Adults Aged 19 to 65. HMSO, London, 2002.
44. R. McCreadie, E. Macdonald, C. Blacklock, et al., Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study, Br. Med. J. 317 (1998) 784-785.
45. S. Brown, J. Birtwistle, L. Roe, C. Thompson, The unhealthy lifestyle of people with schizophrenia, Psychol. Med. 29 (1999) 697-701.
46. M.C. Ryan, J.H. Thakore, Physical consequences of schizophrenia and its treatment; the metabolic syndrome, Life Sci. 71 (2002) 239-257.
47. B.C. Hanson, The metabolic syndrome X, Ann. NY Acad. Sci. 892 (1999) 1-24.
48. M.C. Ryan, P. Collins, J.H. Thakore, Impaired fasting glucose tolerance in first episode, drug-naïve patents with schizophrenia, Am. J. Psychiatry 160 (2003) 284-289.
49. W. Duan, Z. Guo, H. Jiang, M. Ware, M.P. Mattson, Reversal of behavioural and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor, Endocrinology 144 (2003) 2446-2453.
50. L. Pauling, Orthomolecular psychiatry, varying the concentrations of substances normally present in the human body may control mental disease, Science 160 (1968) 265-271.